{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:50:19Z","timestamp":1791967819946,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bbrc.2026.154599","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:16:00Z","timestamp":1789661760000},"page":"154599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A comparative QbD-driven optimization of solid lipid nanoparticles and nanostructured lipid carriers for enhanced drug delivery"],"prefix":"10.1016","volume":"837","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9479-2935","authenticated-orcid":false,"given":"Suriya Prakaash","family":"K K","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4246-5351","authenticated-orcid":false,"given":"Damodharan","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154599_bib1","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/0115748863301630240417071353","article-title":"From evidence to practice: a comprehensive analysis of side effects in synthetic anti-depressant therapy","volume":"20","author":"Pannu","year":"2025","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.bbrc.2026.154599_bib2","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1097\/00008571-200312000-00003","article-title":"Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activity","volume":"13","author":"Kirchheiner","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.bbrc.2026.154599_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/clpt.1984.42","article-title":"Trimipramine kinetics and absolute bioavailability: use of gas-liquid chromatography with nitrogen-phosphorus detection","volume":"35","author":"Abernethy","year":"1984","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2026.154599_bib4","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00406-006-0663-5","article-title":"The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants","volume":"256","author":"Thuerauf","year":"2006","journal-title":"Eur. Arch. Psychiatr. Clin. Neurosci."},{"key":"10.1016\/j.bbrc.2026.154599_bib5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.jcp.0000088909.24613.92","article-title":"Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics","volume":"23","author":"Kirchheiner","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.bbrc.2026.154599_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.22159\/ijcpr.2024v16i1.4020","article-title":"A systematic review on nano drug delivery system: solid lipid nanoparticles (SLN)","author":"Phalak","year":"2024","journal-title":"Int. J. Curr. Pharm. Res."},{"key":"10.1016\/j.bbrc.2026.154599_bib7","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2026.154599_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3390\/pharmaceutics10040191","article-title":"Solid lipid nanoparticles: emerging colloidal nano drug delivery systems","volume":"10","author":"Mishra","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154599_bib9","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/10837450.2022.2084554","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review of the methods of manufacture and routes of administration","volume":"27","author":"Akbari","year":"2022","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.bbrc.2026.154599_bib10","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s11671-025-04234-6","article-title":"Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases","volume":"20","author":"Bairagi","year":"2025","journal-title":"Discover Nano"},{"key":"10.1016\/j.bbrc.2026.154599_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1166\/jbn.2007.049","article-title":"Lipid nanoparticles (SLN\u00ae, NLC\u00ae) for cutaneous drug delivery:Structure, protection and skin effects","volume":"3","author":"Souto","year":"2007","journal-title":"J. Biomed. Nanotechnol."},{"key":"10.1016\/j.bbrc.2026.154599_bib12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.34172\/apb.2023.056","article-title":"An overview of nanostructured lipid carriers and its application in drug delivery through different routes","volume":"13","author":"Khan","year":"2023","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2026.154599_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.69857\/joapr.v13i2.676","article-title":"Nanostructured lipid carriers (NLCs): a comprehensive review of drug delivery advancements","volume":"13","author":"Panwar","year":"2025","journal-title":"J. Appl. Pharm. Res."},{"key":"10.1016\/j.bbrc.2026.154599_bib14","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1080\/17425247.2018.1504018","article-title":"Solid lipid nanocarriers in drug delivery: characterization and design","volume":"15","author":"Mu","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.bbrc.2026.154599_bib15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s13346-024-01681-z","article-title":"Application of quality by design in optimization of nanoformulations: principle, perspectives and practices","volume":"15","author":"Birla","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.bbrc.2026.154599_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1208\/s12248-014-9598-3","article-title":"Understanding pharmaceutical quality by design","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.bbrc.2026.154599_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jddst.2017.02.013","article-title":"Development of efavirenz loaded solid lipid nanoparticles: risk assessment, quality-by-design (QbD) based optimisation and physicochemical characterisation","volume":"39","author":"Raina","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.154599_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2020.105028","article-title":"Luliconazole loaded lyotropic liquid crystalline nanoparticles for topical delivery: QbD driven optimization, in-vitro characterization and dermatokinetic assessment","volume":"234","author":"Mahmood","year":"2021","journal-title":"Chem. Phys. Lipids"},{"key":"10.1016\/j.bbrc.2026.154599_bib19","series-title":"Pharmaceutical Quality by Design","first-page":"255","article-title":"Application of QbD principles in nanocarrier-based drug delivery systems","author":"Rapalli","year":"2019"},{"key":"10.1016\/j.bbrc.2026.154599_bib20","article-title":"QbD-Based development of a pH-Responsive SLN-loaded hydrogel for topical management of biofilm-associated diabetic foot ulcers, recent adv","volume":"20","author":"Parameswaran","year":"2026","journal-title":"Drug Deliv. Formul."},{"key":"10.1016\/j.bbrc.2026.154599_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111548","article-title":"QbD-driven formulation development and evaluation of topical hydrogel containing ketoconazole loaded cubosomes","volume":"119","author":"Rapalli","year":"2021","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.bbrc.2026.154599_bib22","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/0973-8398.134921","article-title":"Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil","volume":"8","author":"Thakkar","year":"2014","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.bbrc.2026.154599_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.15171\/apb.2018.027","article-title":"Preparation and statistical modeling of solid lipid nanoparticles of dimethyl fumarate for better management of multiple sclerosis","volume":"8","author":"Ojha","year":"2018","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bbrc.2026.154599_bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/157016311796799062","article-title":"20 years of lipid Nanoparticles (SLN & NLC): Present State of Development & industrial applications","volume":"8","author":"Muller","year":"2011","journal-title":"Curr. Drug Discov. Technol."},{"key":"10.1016\/j.bbrc.2026.154599_bib25","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3390\/jnt5040012","article-title":"Characteristics and preparation of solid lipid nanoparticles and nanostructured lipid carriers","volume":"5","author":"Queiroz","year":"2024","journal-title":"J. Nanotheranost."},{"key":"10.1016\/j.bbrc.2026.154599_bib26","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3390\/pharmaceutics15020656","article-title":"Current advances in lipid nanosystems intended for topical and transdermal drug delivery applications","volume":"15","author":"Akombaetwa","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154599_bib27","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3390\/pharmaceutics14030533","article-title":"Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy\u2014an overview on recent advances","volume":"14","author":"Jacob","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bbrc.2026.154599_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105438","article-title":"Curcumin loaded nanostructured lipid carriers for enhanced skin retained topical delivery: optimization, scale-up, in-vitro characterization and assessment of ex-vivo skin deposition","volume":"152","author":"Rapalli","year":"2020","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.bbrc.2026.154599_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jddst.2019.04.026","article-title":"Voriconazole loaded nanostructured lipid carriers based topical delivery system: QbD based designing, characterization, in-vitro and ex-vivo evaluation","volume":"52","author":"Waghule","year":"2019","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.154599_bib30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10876-025-02792-4","article-title":"Innovative nanostructured lipid scaffolds for cilnidipine: design and optimization to elevate the therapeutic potential in hypertensive therapy","volume":"36","author":"Mali","year":"2025","journal-title":"J. Clust. Sci."},{"key":"10.1016\/j.bbrc.2026.154599_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0939-6411(98)00074-5","article-title":"Correlation between long-term stability of solid lipid nanoparticles (SLNTM) and crystallinity of the lipid phase","volume":"47","author":"Freitas","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bbrc.2026.154599_bib32","article-title":"Solid lipid nanocarriers embedded hydrogel for topical delivery of apremilast: In-vitro, ex-vivo, dermatopharmacokinetic and anti-psoriatic evaluation","volume":"63","author":"Rapalli","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.bbrc.2026.154599_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.22270\/jddt.v11i1-s.4533","article-title":"Excipients, drug release mechanism and physicochemical characterization methods of solid lipid nanoparticles","volume":"11","author":"Matta","year":"2021","journal-title":"J. Drug Deliv. Therapeut."},{"key":"10.1016\/j.bbrc.2026.154599_bib34","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.colsurfb.2018.03.052","article-title":"Carbamazepine-loaded solid lipid nanoparticles and nanostructured lipid carriers: physicochemical characterization and in vitro\/in vivo evaluation","volume":"167","author":"Scioli Montoto","year":"2018","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.bbrc.2026.154599_bib35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/08982104.2020.1748648","article-title":"Design of temozolomide-loaded proliposomes and lipid crystal nanoparticles with industrial feasible approaches: comparative assessment of drug loading, entrapment efficiency, and stability at plasma pH","volume":"31","author":"Waghule","year":"2021","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.bbrc.2026.154599_bib36","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.molpharmaceut.0c00313","article-title":"Enhancing safety and efficacy by altering the toxic aggregated state of amphotericin B in lipidic nanoformulations","volume":"17","author":"Das","year":"2020","journal-title":"Mol. Pharm."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26013653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:17:56Z","timestamp":1791965876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26013653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":36,"alternative-id":["S0006291X26013653"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154599","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparative QbD-driven optimization of solid lipid nanoparticles and nanostructured lipid carriers for enhanced drug delivery","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154599"}}